These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37376284)

  • 1. Sorafenib-Based Drug Delivery Systems: Applications and Perspectives.
    Wang L; Chen M; Ran X; Tang H; Cao D
    Polymers (Basel); 2023 Jun; 15(12):. PubMed ID: 37376284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.
    Song C; Zhang J; Wen R; Li Q; Zhou J; Xiaoli Liu ; Wu Z; Lv Y; Wu R
    Mater Today Bio; 2022 Dec; 16():100350. PubMed ID: 35856043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
    Li Y; Wei J; Wei Y; Cheng L; Guo B; Meng F; Li F; Zhong Z
    Biomacromolecules; 2020 Feb; 21(2):716-724. PubMed ID: 31809037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
    Wang T; Zhang J; Hou T; Yin X; Zhang N
    Nanoscale; 2019 Aug; 11(29):13934-13946. PubMed ID: 31305839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
    Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
    Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
    Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
    Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
    ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
    Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
    Cai M; Li B; Lin L; Huang J; An Y; Huang W; Zhou Z; Wang Y; Shuai X; Zhu K
    Biomater Sci; 2020 Jun; 8(12):3485-3499. PubMed ID: 32432234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer.
    Kántor I; Dreavă D; Todea A; Péter F; May Z; Biró E; Babos G; Feczkó T
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anticancer effect of flavonoids from Sophora alopecuroides with Sorafenib against hepatocellular carcinoma.
    Zhu XF; Sun ZL; Ma J; Hu B; Yu MC; Liu XJ; Yang P; Xu Y; Ju D; Mu Q
    Phytother Res; 2023 Feb; 37(2):592-610. PubMed ID: 36180975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound-Triggered Nanodroplets for Targeted Co-Delivery of Sorafenib/Doxorubicin for Hepatocellular Carcinoma Therapy.
    Yang T; Ming X; Jie L; Wei W; Guangliang H; Manxia L; Huanling G; Xiangzi S; Chunyang Z; Bai L; Dan W; Zhong C; Xiaoyan X
    J Biomed Nanotechnol; 2019 Sep; 15(9):1881-1896. PubMed ID: 31387676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
    Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
    Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
    AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells.
    Ruman U; Buskaran K; Pastorin G; Masarudin MJ; Fakurazi S; Hussein MZ
    Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33669332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy.
    Ming Y; Li B; Fu R; Xing H; Liu Y; Duan D; Li Z; Li L; Ni R; Xu J; Li C; Xiang M; Song H; Chen J
    J Nanosci Nanotechnol; 2021 Oct; 21(10):5075-5082. PubMed ID: 33875093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.